Skip to main content
Premium Trial:

Request an Annual Quote

Sylentis Picks up Option to Alnylam RNAi IP

Premium

Alnylam Pharmaceuticals said this week that it has granted Sylentis, a Spanish developer of RNAi drugs, a non-exclusive option to license certain of its RNAi-related intellectual property.

According to Alnylam, the option gives Sylentis the chance to develop an siRNA-based treatment for an undisclosed glaucoma target using Alnylam's IP.

Upon execution of the option, Alnylam would receive upfront and milestone payments, and royalties on product sales. Additional terms were not disclosed.

Sylentis is currently conducting a phase I/II trial of an siRNA-based ocular hypertension drug called SYL040012. It targets adrenergic receptor beta-2 and is delivered topically to the eye.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.